PD-L1 expression, assessed by IHC stain 22C3 (Dako) antibody, received U.S. FDA approval for selecting pembrolizumab as first-line and second-line monotherapy in patients with advanced NSCLC [31]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.